MAPT and Alzheimer disease: Experimental models of aging and Alzheimer’s disease (AD), as well as in-human post-mortem and in vivo biomarker-based studies, indicate that the dysregulation of several miRNAs may influence AD pathophysiological mechanisms, including the amyloid-β (Aβ) pathway, tau pathology, brain immune, and inflammatory response, oxidative stress regulation, among others7–16.